Terumo revises FY225 guidance upward, strengthens medical portfolio

Terumo Corporation, on November 12, 2025, revised its full-year financial guidance for FY2025, ending March 31, 2026. This revision is primarily due to the yen's depreciation and steady revenue growth, with assumed exchange rates adjusted to $1=148 yen and €1=169 yen. Previous revenue guidance of 1,050,000m yen was raised to 1,108,000m yen, and adjusted operating profit increased from 214,000m yen to 221,500m yen. However, operating profit and profit attributable to owners of the parent were revised downward to 181,500m yen and 136,000m yen, respectively, impacted by acquisition-related and one-time business portfolio review expenses.

In the first six months of FY2025, total revenue grew 5.2% to 534,930m yen, with overseas revenue up 5.8%. Operating profit surged 15.1% to 100,983m yen, and profit for the period attributable to owners of the parent increased 21.7% to 76,897m yen. The company completed the acquisition of WuXi Biologics' drug product (DP) plant on September 30, 2025, and OrganOx Limited on October 29, 2025, with total consideration for OrganOx around $1.5bn, marking strategic entries into new growth areas.

Total assets increased by 66.4bn yen to 1,894.8bn yen as of September 30, 2025, reflecting investments in manufacturing facilities and business expansion. Cash and cash equivalents stood at 217,155m yen. The company expects a full-year dividend of 30.00 yen per share for FY2025, comprising an interim dividend of 15.00 yen and a year-end dividend of 15.00 yen.